is ozempic a glp 1 agonist or antagonist GLP-1 agonists approved for clinical use. GLP-1 agonists are available Ozempic and GLP-1 Drugs: Risk

Further studies are needed to assess the potential cardiovascular and renal benefits of combination therapy and to determine suitable patient population for the therapy

National Taiwan University researchers highlight the benefits of GLP-1 receptor agonists (GLP-1 RAs) in reducing mortality and severe cardiovascular and renal outcomes for diabetic patients with acute kidney disease (AKD)

CV, cardiovascular

They complement balanced meals, movement, mindfulness, and sleep

Results The pathogenesis of CKD in patients with T2D likely involves many contributors besides hyperglycemia, such as hypertension, obesity, insulin resistance and glomerular atherosclerosis, exerting kidney damage through metabolic, fibrotic, inflammatory, and hemodynamic mechanisms